TWI854148B - Contact lens and contact lens product - Google Patents
Contact lens and contact lens product Download PDFInfo
- Publication number
- TWI854148B TWI854148B TW110130739A TW110130739A TWI854148B TW I854148 B TWI854148 B TW I854148B TW 110130739 A TW110130739 A TW 110130739A TW 110130739 A TW110130739 A TW 110130739A TW I854148 B TWI854148 B TW I854148B
- Authority
- TW
- Taiwan
- Prior art keywords
- light
- contact lens
- blocking
- cdmin
- blocking portion
- Prior art date
Links
- 230000003287 optical effect Effects 0.000 claims abstract description 60
- 238000002834 transmittance Methods 0.000 claims description 58
- 239000000463 material Substances 0.000 claims description 48
- 230000001886 ciliary effect Effects 0.000 claims description 24
- 210000003205 muscle Anatomy 0.000 claims description 24
- 230000003444 anaesthetic effect Effects 0.000 claims description 16
- 238000007654 immersion Methods 0.000 claims description 11
- 150000001875 compounds Chemical class 0.000 claims description 5
- 206010034960 Photophobia Diseases 0.000 abstract description 8
- 230000004075 alteration Effects 0.000 abstract description 7
- 230000002093 peripheral effect Effects 0.000 abstract description 7
- 230000000149 penetrating effect Effects 0.000 abstract 2
- 239000000017 hydrogel Substances 0.000 description 32
- 238000010586 diagram Methods 0.000 description 30
- -1 diarylethene compounds Chemical class 0.000 description 22
- 239000000203 mixture Substances 0.000 description 22
- 230000000694 effects Effects 0.000 description 18
- 239000000178 monomer Substances 0.000 description 18
- 239000000243 solution Substances 0.000 description 15
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 description 14
- 229920001296 polysiloxane Polymers 0.000 description 14
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 13
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 9
- 230000004438 eyesight Effects 0.000 description 9
- 230000004907 flux Effects 0.000 description 9
- 230000000903 blocking effect Effects 0.000 description 8
- XXPBFNVKTVJZKF-UHFFFAOYSA-N 9,10-dihydrophenanthrene Chemical compound C1=CC=C2CCC3=CC=CC=C3C2=C1 XXPBFNVKTVJZKF-UHFFFAOYSA-N 0.000 description 7
- 208000001491 myopia Diseases 0.000 description 7
- 230000004379 myopia Effects 0.000 description 7
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 6
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 6
- 229940088644 n,n-dimethylacrylamide Drugs 0.000 description 6
- YLGYACDQVQQZSW-UHFFFAOYSA-N n,n-dimethylprop-2-enamide Chemical compound CN(C)C(=O)C=C YLGYACDQVQQZSW-UHFFFAOYSA-N 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- PSXPTGAEJZYNFI-UHFFFAOYSA-N 1',3',3'-trimethyl-6-nitrospiro[chromene-2,2'-indole] Chemical compound O1C2=CC=C([N+]([O-])=O)C=C2C=CC21C(C)(C)C1=CC=CC=C1N2C PSXPTGAEJZYNFI-UHFFFAOYSA-N 0.000 description 5
- CQTRKDFIQFOAQV-UHFFFAOYSA-N 1',3',3'-trimethylspiro[benzo[f][1,4]benzoxazine-3,2'-indole] Chemical compound C1=CC=CC2=C(N=CC3(C(C)(C)C4=CC=CC=C4N3C)O3)C3=CC=C21 CQTRKDFIQFOAQV-UHFFFAOYSA-N 0.000 description 5
- 210000005252 bulbus oculi Anatomy 0.000 description 5
- 210000004087 cornea Anatomy 0.000 description 5
- 239000004205 dimethyl polysiloxane Substances 0.000 description 5
- 210000001508 eye Anatomy 0.000 description 5
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 5
- 210000001747 pupil Anatomy 0.000 description 5
- 201000009310 astigmatism Diseases 0.000 description 4
- 239000011248 coating agent Substances 0.000 description 4
- 238000000576 coating method Methods 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000007639 printing Methods 0.000 description 4
- 238000002791 soaking Methods 0.000 description 4
- 230000000007 visual effect Effects 0.000 description 4
- SYVIGZKZIQYSFC-CAPFRKAQSA-N (4e)-3-benzhydrylidene-4-benzylideneoxolane-2,5-dione Chemical compound C=1C=CC=CC=1\C=C/1C(=O)OC(=O)C\1=C(C=1C=CC=CC=1)C1=CC=CC=C1 SYVIGZKZIQYSFC-CAPFRKAQSA-N 0.000 description 3
- BYTODYRJYJMSEV-UHFFFAOYSA-N 3-hydroxy-4-methylbenzo[h]chromen-2-one Chemical compound OC1=C(C2=C(OC1=O)C1=CC=CC=C1C=C2)C BYTODYRJYJMSEV-UHFFFAOYSA-N 0.000 description 3
- IZDVWQPIYXTGIF-UHFFFAOYSA-N 8-methoxy-1',3',3'-trimethyl-6-nitrospiro[chromene-2,2'-indole] Chemical compound CN1C2=CC=CC=C2C(C)(C)C11C=CC(C=C(C=C2OC)[N+]([O-])=O)=C2O1 IZDVWQPIYXTGIF-UHFFFAOYSA-N 0.000 description 3
- 206010020675 Hypermetropia Diseases 0.000 description 3
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000008020 evaporation Effects 0.000 description 3
- 238000001704 evaporation Methods 0.000 description 3
- 201000006318 hyperopia Diseases 0.000 description 3
- 230000004305 hyperopia Effects 0.000 description 3
- 230000001769 paralizing effect Effects 0.000 description 3
- 210000001525 retina Anatomy 0.000 description 3
- 229910000077 silane Inorganic materials 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- HKGODBTXGKITRZ-UHFFFAOYSA-N 1',3',3'-trimethylspiro[2,4-dihydrophenanthro[9,10-b][1,4]oxazine-3,2'-indole] Chemical compound C12=CC=CC=C2C2=CC=CC=C2C(OC2)=C1NC12C(C)(C)C2=CC=CC=C2N1C HKGODBTXGKITRZ-UHFFFAOYSA-N 0.000 description 2
- BESKSSIEODQWBP-UHFFFAOYSA-N 3-tris(trimethylsilyloxy)silylpropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCCC[Si](O[Si](C)(C)C)(O[Si](C)(C)C)O[Si](C)(C)C BESKSSIEODQWBP-UHFFFAOYSA-N 0.000 description 2
- VODQUQTUKIYWSU-UHFFFAOYSA-N 5'-chloro-1',3',3'-trimethylspiro[benzo[f][1,4]benzoxazine-3,2'-indole] Chemical compound C1=CC=CC2=C(N=CC3(C(C)(C)C4=CC(Cl)=CC=C4N3C)O3)C3=CC=C21 VODQUQTUKIYWSU-UHFFFAOYSA-N 0.000 description 2
- 229930003347 Atropine Natural products 0.000 description 2
- 102000014415 Muscarinic acetylcholine receptor Human genes 0.000 description 2
- 108050003473 Muscarinic acetylcholine receptor Proteins 0.000 description 2
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 2
- RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- SKYSRIRYMSLOIN-UHFFFAOYSA-N cyclopentolate Chemical compound C1CCCC1(O)C(C(=O)OCCN(C)C)C1=CC=CC=C1 SKYSRIRYMSLOIN-UHFFFAOYSA-N 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 201000010041 presbyopia Diseases 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000002441 reversible effect Effects 0.000 description 2
- RXMIJUXQTYPPFM-WUXMJOGZSA-N (3E)-3-[2-(2,5-dimethylfuran-3-yl)ethylidene]-4-propan-2-ylideneoxolane-2,5-dione Chemical compound CC(C)=C1C(=O)OC(=O)\C1=C\CC1=C(C)OC(C)=C1 RXMIJUXQTYPPFM-WUXMJOGZSA-N 0.000 description 1
- QRIMLDXJAPZHJE-UHFFFAOYSA-N 2,3-dihydroxypropyl 2-methylprop-2-enoate Chemical compound CC(=C)C(=O)OCC(O)CO QRIMLDXJAPZHJE-UHFFFAOYSA-N 0.000 description 1
- QSAVEGSLJISCDF-UHFFFAOYSA-N 2-hydroxy-2-phenylacetic acid (1,2,2,6-tetramethyl-4-piperidinyl) ester Chemical compound C1C(C)(C)N(C)C(C)CC1OC(=O)C(O)C1=CC=CC=C1 QSAVEGSLJISCDF-UHFFFAOYSA-N 0.000 description 1
- VCMLCMCXCRBSQO-UHFFFAOYSA-N 3h-benzo[f]chromene Chemical class C1=CC=CC2=C(C=CCO3)C3=CC=C21 VCMLCMCXCRBSQO-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 208000032170 Congenital Abnormalities Diseases 0.000 description 1
- 206010061788 Corneal infection Diseases 0.000 description 1
- ZTVIKZXZYLEVOL-MCOXGKPRSA-N Homatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(O)C1=CC=CC=C1 ZTVIKZXZYLEVOL-MCOXGKPRSA-N 0.000 description 1
- RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 206010047571 Visual impairment Diseases 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229940035674 anesthetics Drugs 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 229960000396 atropine Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229960001815 cyclopentolate Drugs 0.000 description 1
- 150000001988 diarylethenes Chemical class 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 208000029436 dilated pupil Diseases 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 229950002420 eucatropine Drugs 0.000 description 1
- 239000003193 general anesthetic agent Substances 0.000 description 1
- 229960000857 homatropine Drugs 0.000 description 1
- 238000002430 laser surgery Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002637 mydriatic agent Substances 0.000 description 1
- 230000002911 mydriatic effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 210000005037 parasympathetic nerve Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000010344 pupil dilation Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 230000035807 sensation Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229960004791 tropicamide Drugs 0.000 description 1
- 230000004393 visual impairment Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
Images
Landscapes
- Eyeglasses (AREA)
Abstract
Description
本發明是有關於一種隱形眼鏡及隱形眼鏡產品,且特別是有關於一種可以控制光通量並改善成像品質的隱形眼鏡及隱形眼鏡產品。The present invention relates to a contact lens and a contact lens product, and in particular to a contact lens and a contact lens product capable of controlling light flux and improving imaging quality.
眼睛為靈魂之窗,然而,由於先天缺陷或後天使用不當,導致視力不正常的人口比例逐漸攀升。常見的視力問題包括近視、遠視或散光,其中近視患者是由於角膜的屈光度較強而導致影像聚焦於視網膜之前,遠視患者則由於角膜的屈光度較弱而導致影像聚焦於視網膜之後,散光患者則因不同區域的眼角膜表面弧度不均或是角膜表面凹凸不平,而使光線不能準確地聚焦在視網膜上形成清晰的影像。Eyes are the windows to the soul. However, due to congenital defects or improper use, the proportion of people with abnormal vision is gradually increasing. Common vision problems include myopia, hyperopia or astigmatism. Myopia patients have a strong corneal refractive power, which causes the image to focus in front of the retina. Hyperopia patients have a weak corneal refractive power, which causes the image to focus behind the retina. Astigmatism patients have uneven curvature of the corneal surface in different areas or uneven corneal surface, which makes it impossible for light to focus accurately on the retina to form a clear image.
為了矯正前述視力問題,一般患者會配戴有框架的眼鏡或者隱形眼鏡,其中有框架的眼鏡不利於從事戶外活動且有礙美觀,故隱形眼鏡的配戴者逐漸攀升。In order to correct the aforementioned vision problems, patients generally wear glasses with frames or contact lenses. Glasses with frames are not conducive to outdoor activities and affect the aesthetics, so the number of contact lens wearers is gradually increasing.
然而,習用隱形眼鏡控制光通量的效果不彰,過多的光通量易導致畏光問題,過少的光通量則會造成影像幽暗不清,因此,如何改良隱形眼鏡的結構及/或材質,以有效控制光通量,亦即一方面可避免過多光線進入眼睛而避免畏光問題,另一方面可維持充足的光通量以確保影像的明亮度,遂成為相關業者、學者努力的目標。However, the effect of using contact lenses to control light flux is not satisfactory. Too much light flux can easily lead to photophobia, while too little light flux will cause the image to be dark and unclear. Therefore, how to improve the structure and/or material of contact lenses to effectively control light flux, that is, on the one hand, to prevent too much light from entering the eyes and avoid photophobia, and on the other hand, to maintain sufficient light flux to ensure the brightness of the image, has become the goal of relevant industry practitioners and scholars.
本發明之一目的是提供一種隱形眼鏡,其包含阻光環型區,藉此,可避免過多光線進入並可兼顧充足通光量,而可減輕畏光問題,並可進一步消除周邊像差,而可提升視野範圍內影像的清晰度和銳利度。One object of the present invention is to provide a contact lens comprising a light-blocking annular zone, thereby preventing excessive light from entering and taking into account sufficient light throughput, thereby alleviating the problem of photophobia, and further eliminating peripheral aberrations, thereby improving the clarity and sharpness of images within the field of vision.
依據本發明提供一種隱形眼鏡,包含一光學區以及至少一阻光環型區,阻光環型區環繞隱形眼鏡的中心點設置。阻光環型區包含至少二阻光部,二阻光部由內到外分別為一第一阻光部以及一第二阻光部,且第一阻光部及第二阻光部之間具有間隙。According to the present invention, a contact lens is provided, comprising an optical zone and at least one light-blocking annular zone, the light-blocking annular zone being arranged around the center point of the contact lens. The light-blocking annular zone comprises at least two light-blocking portions, the two light-blocking portions are respectively a first light-blocking portion and a second light-blocking portion from the inside to the outside, and there is a gap between the first light-blocking portion and the second light-blocking portion.
依據本發明另提供一種隱形眼鏡產品,包含前段所述的隱形眼鏡以及一浸潤溶液,隱形眼鏡浸泡於浸潤溶液中。隱形眼鏡與浸潤溶液中至少一者包含一睫狀肌麻痺劑。According to the present invention, a contact lens product is provided, comprising the contact lens described in the previous paragraph and an immersion solution, wherein the contact lens is immersed in the immersion solution. At least one of the contact lens and the immersion solution contains a ciliary muscle paralytic.
第1A圖是繪示依照本發明一實施方式的一種隱形眼鏡10的示意圖。第1A圖中,隱形眼鏡10包含光學區11以及阻光環型區12,阻光環型區12環繞隱形眼鏡10的中心點O設置。FIG. 1A is a schematic diagram showing a
具體來說,第1A圖中,光學區11是指虛線所圍起的區域,阻光環型區12是指灑點處的區域。在本實施方式中,光學區11與阻光環型區12有部分重疊,但在其他實施方式中,光學區11與阻光環型區12可完全錯開。此外,阻光環型區12可與隱形眼鏡10同心,阻光環型區12亦可與隱形眼鏡10不同心。Specifically, in FIG. 1A , the optical zone 11 refers to the area enclosed by the dotted line, and the light-blocking annular area 12 refers to the area at the sprinkler point. In this embodiment, the optical zone 11 and the light-blocking annular area 12 partially overlap, but in other embodiments, the optical zone 11 and the light-blocking annular area 12 may be completely staggered. In addition, the light-blocking annular area 12 may be concentric with the
阻光環型區12於可見光(400 nm~700 nm)的平均穿透率為Tavg,其滿足下列條件:0% < Tavg ≤ 60%。藉此,可避免過多光線進入並可兼顧充足光通量,而可減輕畏光問題,並可進一步消除周邊像差,而可提升視野範圍內影像的清晰度和銳利度。或者,其可滿足下列條件:0% < Tavg ≤ 50%。或者,其可滿足下列條件:1% < Tavg ≤ 50%。或者,其可滿足下列條件:0% < Tavg ≤ 40%。或者,其可滿足下列條件:5% < Tavg ≤ 40%。或者,其可滿足下列條件:0% < Tavg ≤ 30%。或者,其可滿足下列條件:10% < Tavg ≤ 30%。或者,其可滿足下列條件:0% < Tavg ≤ 20%。或者,其可滿足下列條件:10% < Tavg ≤ 20%。或者,其可滿足下列條件:0% < Tavg ≤ 10%。The average transmittance of the light-blocking annular region 12 in visible light (400 nm~700 nm) is Tavg, which satisfies the following conditions: 0% < Tavg ≤ 60%. In this way, excessive light can be prevented from entering and sufficient luminous flux can be taken into account, thereby alleviating the problem of photophobia, and further eliminating peripheral aberrations, thereby improving the clarity and sharpness of the image within the field of vision. Alternatively, it can meet the following conditions: 0% < Tavg ≤ 50%. Alternatively, it can meet the following conditions: 1% < Tavg ≤ 50%. Alternatively, it can meet the following conditions: 0% < Tavg ≤ 40%. Alternatively, it can meet the following conditions: 5% < Tavg ≤ 40%. Alternatively, it can meet the following conditions: 0% < Tavg ≤ 30%. Alternatively, it may satisfy the following conditions: 10% < Tavg ≤ 30%. Alternatively, it may satisfy the following conditions: 0% < Tavg ≤ 20%. Alternatively, it may satisfy the following conditions: 10% < Tavg ≤ 20%. Alternatively, it may satisfy the following conditions: 0% < Tavg ≤ 10%.
阻光環型區12的最小直徑為CDmin,隱形眼鏡10的最大直徑為D,其滿足下列條件:0.01 ≤ CDmin/D ≤ 0.80。藉此,可避免過多光線進入並可兼顧充足光通量,而可減輕畏光問題,並可進一步消除周邊像差,而可提升視野範圍內影像的清晰度和銳利度。或者,其可滿足下列條件:0.01 ≤ CDmin/D ≤ 0.45。或者,其可滿足下列條件:0.05 ≤ CDmin/D ≤ 0.45。或者,其可滿足下列條件:0.10 ≤ CDmin/D ≤ 0.40。或者,其可滿足下列條件:0.20 ≤ CDmin/D ≤ 0.40。The minimum diameter of the light-blocking annular area 12 is CDmin, and the maximum diameter of the
阻光環型區12可包含至少二阻光部(可參照第4圖),且不同阻光部間可具有間隙,亦可設計為緊密相連。藉此,可進一步降低可見光的通過量,而提升減輕畏光的效果。The light-blocking annular area 12 may include at least two light-blocking parts (see FIG. 4 ), and different light-blocking parts may have gaps between them or be designed to be closely connected. In this way, the amount of visible light passing through can be further reduced, thereby enhancing the effect of reducing photophobia.
阻光環型區12的多個阻光部於可見光的平均穿透率可為漸層式變化,意即不同阻光部可具有不同的顏色深淺變化設計,其顏色由內到外可設計深到淺(Tavg1<Tavg2,其中Tavg1、Tavg2分別為由內而外的第一阻光部及第二阻光部於可見光的平均穿透率),亦可設計為淺到深(Tavg1>Tavg2),若存在更多的阻光部則可進一步設計為由深到淺再到深(Tavg1<Tavg2且Tavg3<Tavg2,其中Tavg1、Tavg2、Tavg3分別為由內而外的第一阻光部、第二阻光部及第三阻光部於可見光的平均穿透率),亦可為由淺到深再到淺(Tavg1>Tavg2 且 Tavg3>Tavg2)的波浪式顏色深度漸層變化。藉此,可以有效變化控制阻擋可見光的效果,以漸層式的設計視需求強化阻擋範圍並兼顧視覺美觀效果。The average transmittance of the multiple light-blocking parts of the light-blocking annular region 12 in visible light can be changed in a gradient manner, that is, different light-blocking parts can have different color depth change designs, and the color can be designed to be dark to light from the inside to the outside (Tavg1<Tavg2, where Tavg1 and Tavg2 are the average transmittance of the first light-blocking part and the second light-blocking part from the inside to the outside in visible light, respectively), or can be designed to be light to dark (Tavg 1>Tavg2), if there are more light-blocking parts, it can be further designed from deep to shallow and then to deep (Tavg1<Tavg2 and Tavg3<Tavg2, where Tavg1, Tavg2, and Tavg3 are the average transmittance of the first light-blocking part, the second light-blocking part, and the third light-blocking part from the inside to the outside in visible light, respectively), or it can be a wave-like color depth gradient change from shallow to deep and then to shallow (Tavg1>Tavg2 and Tavg3>Tavg2). In this way, the effect of blocking visible light can be effectively changed and controlled, and the blocking range can be strengthened according to needs with a gradient design while taking into account the visual aesthetic effect.
阻光環型區的阻光部可進一步包含複數個微阻光部(可參照第15圖),此些微阻光部可呈輻射狀排列方式,且此些微阻光部於可見光的平均穿透率可為漸層式變化,意即不同微阻光部可沿著順時針方向或逆時針方向具有不同的顏色深淺變化。藉此,可強化視覺美觀效果並具有旋轉定位辨識功能。The light-blocking portion of the light-blocking annular area may further include a plurality of micro light-blocking portions (see FIG. 15 ), which may be arranged in a radial manner, and the average transmittance of the micro light-blocking portions in visible light may change gradually, that is, different micro light-blocking portions may have different color depth changes along the clockwise direction or the counterclockwise direction. In this way, the visual aesthetic effect can be enhanced and the rotation positioning recognition function can be provided.
阻光環型區12的最大直徑為CDmax,阻光環型區12的最小直徑為CDmin,其可滿足下列條件:0.5 mm ≤ CDmax-CDmin ≤ 13.0 mm。藉此,阻光環型區12的大小適當,有助於提升視覺舒適性並符合美觀需求。或者,其可滿足下列條件:1.0 mm ≤ CDmax-CDmin ≤ 12.0 mm。或者,其可滿足下列條件:1.5 mm ≤ CDmax-CDmin ≤ 11.0 mm。或者,其可滿足下列條件:2.0 mm ≤ CDmax-CDmin ≤ 10.0 mm。或者,其可滿足下列條件:3.0 mm ≤ CDmax-CDmin ≤ 9.0 mm。或者,其可滿足下列條件:3.0 mm ≤ CDmax-CDmin ≤ 8.0 mm。The maximum diameter of the light-blocking annular area 12 is CDmax, and the minimum diameter of the light-blocking annular area 12 is CDmin, which can meet the following conditions: 0.5 mm ≤ CDmax-CDmin ≤ 13.0 mm. Thus, the size of the light-blocking annular area 12 is appropriate, which helps to improve visual comfort and meet aesthetic requirements. Alternatively, it can meet the following conditions: 1.0 mm ≤ CDmax-CDmin ≤ 12.0 mm. Alternatively, it can meet the following conditions: 1.5 mm ≤ CDmax-CDmin ≤ 11.0 mm. Alternatively, it can meet the following conditions: 2.0 mm ≤ CDmax-CDmin ≤ 10.0 mm. Alternatively, it can meet the following conditions: 3.0 mm ≤ CDmax-CDmin ≤ 9.0 mm. Alternatively, it may meet the following conditions: 3.0 mm ≤ CDmax-CDmin ≤ 8.0 mm.
阻光環型區12的最小直徑為CDmin,光學區11的最大直徑為OD,其可滿足下列條件:0.05 ≤ CDmin/OD ≤ 2.0。藉此,有助於維持適當的進光量,可確保明暗度適中的視覺成像效果。或者,其可滿足下列條件:0.10 ≤ CDmin/OD ≤ 1.80。或者,其可滿足下列條件:0.15 ≤ CDmin/OD ≤ 1.60。或者,其可滿足下列條件:0.15 ≤ CDmin/OD ≤ 1.40。或者,其可滿足下列條件:0.20 ≤ CDmin/OD ≤ 1.00。或者,其可滿足下列條件:0.20 ≤ CDmin/OD ≤ 0.85。The minimum diameter of the light-blocking annular area 12 is CDmin, and the maximum diameter of the optical area 11 is OD, which can meet the following conditions: 0.05 ≤ CDmin/OD ≤ 2.0. This helps maintain an appropriate amount of light input and ensures a visual imaging effect with moderate brightness. Alternatively, it can meet the following conditions: 0.10 ≤ CDmin/OD ≤ 1.80. Alternatively, it can meet the following conditions: 0.15 ≤ CDmin/OD ≤ 1.60. Alternatively, it can meet the following conditions: 0.15 ≤ CDmin/OD ≤ 1.40. Alternatively, it can meet the following conditions: 0.20 ≤ CDmin/OD ≤ 1.00. Alternatively, it can meet the following conditions: 0.20 ≤ CDmin/OD ≤ 0.85.
在本實施方式中,阻光環型區12的內周緣12A為圓形,在其他實施方式中,阻光環型區12的內周緣12A可為具有至少四個邊的多邊形(可參照第7圖至第10圖)。藉此,可依消費者需求設計進行多樣化變化以避免單調圖樣,更可提供散光矯正、老花矯正或多焦點式鏡片的旋轉穩定方向確認與辨識。In this embodiment, the inner periphery 12A of the light-blocking annular area 12 is circular, and in other embodiments, the inner periphery 12A of the light-blocking annular area 12 may be a polygon with at least four sides (see FIGS. 7 to 10 ). In this way, the design can be diversified according to consumer needs to avoid monotonous patterns, and can also provide rotational stability direction confirmation and identification of astigmatism correction, presbyopia correction or multi-focal lenses.
隱形眼鏡10可包含光致變色材料(photochromic materials),藉此,有利於在戶外強光環境下減少強光對眼睛的刺激與傷害,並可加強阻光環型區12的可見光阻擋隔絕效果,提升光源強度變化劇烈的環境適用性。The
所述光致變色材料是指一種物質(A)其受到一定波長的光照射時會發生化學反應而轉變成另一物質(B),而所生成的另一物質(B)在光或熱的作用下,會發生可逆化學反應而返回原物質(A),原物質(A)與另一物質(B)的吸收光譜有差異而呈現不同的顏色。具體來說,光致變色材料可為但不限於螺吡喃類化合物(spiropyrans)、螺1,4-氧氮六圜類化合物(spirooxazines)、萘并吡喃類化合物(benzo and naphthopyrans)、俘精酸酐類化合物(fulgides)、二芳基乙烯類化合物(diarylethenes)或其組合。前述「其組合」是指光致變色材料可包含螺吡喃類化合物、螺1,4-氧氮六圜類化合物、萘并吡喃類化合物、俘精酸酐類化合物、二芳基乙烯類化合物中至少兩種,且可以任意比例進行混合。舉例來說,螺吡喃類化合物可為但不限於1′,3′-二氫-1′,3′,3′-三甲基-6-硝基螺[2H-1-苯并吡喃-2,2′-(2H)-吲哚] (1′,3′-dihydro-1′,3′,3′-trimethyl-6-nitrospiro[2H-1-benzopyran-2,2′-(2H)-indole];CAS號為1498-88-0)或1′,3′-二氫-8-甲氧基-1′,3′,3′-三甲基-6-硝基螺[2H-1-苯并吡喃-2,2′-(2H)-吲哚](1′,3′-dihydro-8-methoxy-1′,3′,3′-trimethyl-6-nitrospiro[2H-1-benzopyran-2,2′-(2H)- indole];CAS號為1498-89-1)。螺1,4-氧氮六圜類化合物可為但不限於1,3-二氫-1,3,3-三甲基螺[2H-吲哚-2,3′-[3H]萘并[2,1-b][1,4]嗪] (1,3-dihydro-1,3,3-trimethylspiro[2H-indole-2,3′-[3H]naphth[2,1-b][1,4]oxazine];CAS號為27333-47-7)或5-氯-1,3-二氫-1,3,3-三甲基螺[2H-吲哚-2,3′-(3H)萘并[2,1-b](1,4)嗪](5-chloro-1,3-dihydro-1,3,3-trimethylspiro[2H-indole-2,3′-(3H)naphth[2,1-b](1,4)oxazine];CAS號為27333-50-2)或1,3-二氫-1,3,3-三甲基螺[2H-吲哚-2,3′-[3H]菲并[9,10-b](1,4)嗪] (1,3-dihydro-1,3,3-trimethylspiro[2H-indole-2,3′-[3H]phenanthro[9,10-b](1,4)oxazine];CAS號為119980-36-8)。萘并吡喃類化合物可為但不限於羥基-4-甲基-2H-萘并(1,2-B)吡喃-2-酮 (hydroxy-4-methyl-2H-naphtho(1,2-B)pyran-2-one;CAS號為21353-16-2)。俘精酸酐類化合物可為但不限於(E)-亞苄基(二苯亞甲基)琥珀酸酐((E)-benzylidene (diphenylmethylene) succinic anhydride;CAS號為37460-01-8)或3-[(E)-2-(2,5-二甲基呋喃-3-基)亞乙基]二氫-4-(1-甲基亞乙基)-2,5-呋喃二酮(3-[(E)-2-(2,5-dimethylfuran-3-yl)ethylidene]dihydro-4-(1-methylethylidene)-2,5-furandione;CAS號為77515-04-9)。二芳基乙烯類化合物可為但不限於9,10-二氫菲(9,10-dihydrophenanthrene;CAS號為776-35-2)。The photochromic material refers to a substance (A) that undergoes a chemical reaction and transforms into another substance (B) when exposed to light of a certain wavelength, and the generated another substance (B) undergoes a reversible chemical reaction under the action of light or heat and returns to the original substance (A), and the absorption spectra of the original substance (A) and the another substance (B) are different and present different colors. Specifically, the photochromic material can be, but is not limited to, spiropyrans, spirooxazines, benzo and naphthopyrans, fulgides, diarylethenes, or a combination thereof. The aforementioned "combination thereof" means that the photochromic material may include at least two of spiropyran compounds, spiro-1,4-oxadiazine compounds, naphthopyran compounds, fulgide compounds, and diarylethene compounds, and they may be mixed in any proportion. For example, the spiropyran compound may be, but is not limited to, 1',3'-dihydro-1',3',3'-trimethyl-6-nitrospiro[2H-1-benzopyran-2,2'-(2H)-indole] (1′,3′-dihydro-1′,3′,3′-trimethyl-6-nitrospiro[2H-1-benzopyran-2,2′-(2H)-indole]; CAS number: 1498-88-0) or 1′,3′-dihydro-8-methoxy-1′,3′,3′-trimethyl-6-nitrospiro[2H-1-benzopyran-2,2′-(2H)-indole] (1′,3′-dihydro-8-methoxy-1′,3′,3′-trimethyl-6-nitrospiro[2H-1-benzopyran-2,2′-(2H)-indole]; CAS number: 1498-89-1). The spiro-1,4-oxazine compound may be, but is not limited to, 1,3-dihydro-1,3,3-trimethylspiro[2H-indole-2,3′-[3H]naphth[2,1-b][1,4]oxazine] (CAS No. 27333-47-7) or 5-chloro-1,3-dihydro-1,3,3-trimethylspiro[2H-indole-2,3′-[3H]naphth[2,1-b][1,4]oxazine] (CAS No. 27333-47-7). chloro-1,3-dihydro-1,3,3-trimethylspiro[2H-indole-2,3′-(3H)naphth[2,1-b](1,4)oxazine]; CAS number is 27333-50-2) or 1,3-dihydro-1,3,3-trimethylspiro[2H-indole-2,3′-[3H]phenanthro[9,10-b](1,4)oxazine] (1,3-dihydro-1,3,3-trimethylspiro[2H-indole-2,3′-[3H]phenanthro[9,10-b](1,4)oxazine]; CAS number is 119980-36-8). The naphthopyran compound may be, but is not limited to, hydroxy-4-methyl-2H-naphtho(1,2-B)pyran-2-one (CAS No. 21353-16-2). The fulgide compound may be, but is not limited to, (E)-benzylidene (diphenylmethylene) succinic anhydride (CAS No. 37460-01-8) or 3-[(E)-2-(2,5-dimethylfuran-3-yl)ethylidene]dihydro-4-(1-methylethylidene)-2,5-furandione (CAS No. 77515-04-9). The diarylethene compound may be, but is not limited to, 9,10-dihydrophenanthrene (CAS No. 776-35-2).
具體來說,光學區11與阻光環型區12至少一者可包含光致變色材料,亦即,可僅光學區11包含光致變色材料,或可僅阻光環型區12包含光致變色材料,或者可光學區11與阻光環型區12同時包含光致變色材料。當光學區11包含光致變色材料時,隱形眼鏡10可於具有強光的戶外環境下發揮有如太陽眼鏡的功效,減少強光對眼睛的刺激與傷害。當阻光環型區12包含光致變色材料時,可加強阻光環型區12的可見光阻擋隔絕效果,可於室內或戶外皆可有效使用,提升光源強度變化劇烈的環境適用性。Specifically, at least one of the optical zone 11 and the light-blocking annular zone 12 may include a photochromic material, that is, only the optical zone 11 may include a photochromic material, or only the light-blocking annular zone 12 may include a photochromic material, or both the optical zone 11 and the light-blocking annular zone 12 may include a photochromic material. When the optical zone 11 includes a photochromic material, the
更具體來說,光致變色材料可加入製作隱形眼鏡10的組成物中,藉此,整片隱形眼鏡10皆具有光致變色的效果。或者,光致變色材料可僅添加於隱形眼鏡10的局部,例如,隱形眼鏡10可為採三明治製程的雙膜層隱形眼鏡,雙膜層隱形眼鏡包含物側層(圖未揭示)與像側層(圖未揭示)二主體結構,且物側層與像側層中具有彩色薄膜(圖未揭示),彩色薄膜可以印刷、蒸鍍、塗佈等方式形成於物側層與像側層的表面上,且彩色薄膜可形成於物側層與像側層的表面上的特定區塊並可具有不同的圖案變化,此時,光致變色材料可添加於物側層及/或像側層,例如,可混摻於製作物側層及/或像側層的組成物中,使物側層及/或像側層整體具有光致變色效果,或者,光致變色材料可以印刷、蒸鍍、塗佈等方式形成於物側層及/或像側層的表面上(可局部或完整覆蓋),又或者,光致變色材料可添加於形成彩色薄膜的彩色顏料中,成為彩色薄膜的一部分而形成於物側層與像側層的表面上的特定區塊並可具有不同的圖案變化。More specifically, the photochromic material can be added to the composition of the
隱形眼鏡10的材質可為矽水膠,且製備矽水膠的組成物可包含至少三種單體,單體可為甲基丙烯酸羥乙酯(2-hydroxyethyl methacrylate)、甲基丙烯酸(methacrylic acid)、2-甲基-2-丙烯酸-2,3-二羥基丙酯(glycerol monomethacrylate)、N-乙烯基-2-吡咯酮(N-vinyl-2-pyrrolidinone)、N,N-二甲基丙烯醯胺(N,N-dimethyl acrylamide)、甲基丙烯醯氧丙基三(三甲基矽氧烷基)矽烷(3-methacryloyloxypropyltris (trimethylsilyloxy) silane)、(3-甲基丙烯醯氧基-2-羥基丙氧基)丙基双(三甲基矽氧基)甲基(3-(3-methacryloxy-2-hydroxypropoxy) propylbis (trimethylsiloxy) methylsilane)、3-乙醯氧基-2-羥基丙氧基丙基封端的聚二甲基矽氧烷((3-acryloxy-2-hydroxypropoxypropyl) terminated polydimethylsiloxane)或甲基丙烯酸甲酯(methyl methacrylate),也就是說可由前述單體中選出至少三種作為製備矽水膠組成物中的單體成分,關於矽水膠組成物的其他成分係為習用,在此不予贅述。藉此,隱形眼鏡10具有較佳的透氧率,可提供長時間配戴的舒適感。The
隱形眼鏡10的材質可為水膠,且製備水膠的組成物可包含至少二種單體,單體可為甲基丙烯酸羥乙酯、甲基丙烯酸、2-甲基-2-丙烯酸-2,3-二羥基丙酯、N-乙烯基-2-吡咯酮、N,N-二甲基丙烯醯胺、甲基丙烯醯氧丙基三(三甲基矽氧烷基)矽烷、(3-甲基丙烯醯氧基-2-羥基丙氧基)丙基双(三甲基矽氧基)甲基、3-乙醯氧基-2-羥基丙氧基丙基封端的聚二甲基矽氧烷或甲基丙烯酸甲酯,也就是說可由前述單體中選出至少二種作為製備水膠組成物中的單體成分,關於水膠組成物的其他成分係為習用,在此不予贅述。藉此,隱形眼鏡10具有較佳的含水率與舒適性,可維持隱形眼鏡10的濕潤、滑順與柔軟舒適的水潤感,並避免配戴時的異物感。The material of the
隱形眼鏡10可為多焦點隱形眼鏡。藉此,有利於矯正散光、老花、近視與遠視,當應用於矯正近視,進一步更可提供減緩近視的視力控制效果。The
阻光環型區12最大直徑為CDmax,隱形眼鏡10的最大直徑為D,其可滿足下列條件:0.5 ≤ CDmax/D ≤ 1.0。藉此,阻光環型區12可於戶外環境下產生增大瞳孔面積的效果,並減緩於戶外的強光傷害。或者,其可滿足下列條件:0.55 ≤ CDmax/D ≤ 1.00。或者,其可滿足下列條件:0.65 ≤ CDmax/D ≤ 1.00。或者,其可滿足下列條件:0.75 ≤ CDmax/D ≤ 1.00。或者,其可滿足下列條件:0.80 ≤ CDmax/D ≤ 0.95。The maximum diameter of the light-blocking annular zone 12 is CDmax, and the maximum diameter of the
請參照第1B圖,其係繪示第1A圖中隱形眼鏡10的側視示意圖。第1B圖中,隱形眼鏡10的基弧(base curve)為BC,其可滿足下列條件:9.00mm ≤ BC。藉此,隱形眼鏡10可提供曲率半徑較大的基弧,有助於服貼於較平整的角膜,而可提升配戴舒適性與貼服度。例如,進行過雷射角膜手術後的患者,由於角膜經手術切除後較為平整,一般隱形眼鏡的基弧無法達到有效的舒適性與完整貼服度,因此本發明的隱形眼鏡10有利於進行過雷射角膜手術後的患者配戴。或者,其可滿足下列條件:9.25mm ≤ BC。或者,其可滿足下列條件:9.50mm ≤ BC。或者,其可滿足下列條件:9.75mm ≤ BC。或者,其可滿足下列條件:10.00mm ≤ BC ≤ 100.00mm。Please refer to FIG. 1B, which is a schematic side view of the
具體來說,基弧是指隱形眼鏡10貼近眼角膜的後表面(未另標號)的弧度。基弧越大是指隱形眼鏡10的後表面越平坦,當隱形眼鏡10的基弧大於眼球的基弧,將導致隱形眼鏡10無法伏貼於眼球表面而容易發生位移問題,反之隱形眼鏡10的基弧小於眼球的基弧,則容易產生過度緊繃與不舒適感,因此,當隱形眼鏡10的基弧與眼球的基弧差異較大,易導致視力波動或隱形眼鏡10脫落,甚至造成角膜感染。一般設計多使隱形眼鏡10的基弧比角膜的基弧大約0.4mm,國人眼球的基弧約介於8.4mm~8.6mm間,所以目前市面上的隱形眼鏡基弧多設計為9mm以下,並不適用於近視雷射手術後患者因手術而具有較平整的角膜。Specifically, the base curve refers to the curvature of the rear surface (not separately labeled) of the
第2圖是繪示依照本發明另一實施方式的一種隱形眼鏡產品30的示意圖。第2圖中,隱形眼鏡產品30包含隱形眼鏡10以及浸潤溶液20,隱形眼鏡10浸泡於浸潤溶液20中,關於隱形眼鏡10的細節請參照前文,在此不予贅述。浸潤溶液20可為市面上用於浸泡、保存隱形眼鏡的溶液。FIG. 2 is a schematic diagram showing a
隱形眼鏡10與浸潤溶液20中至少一者可包含睫狀肌麻痺劑。亦即,可僅隱形眼鏡10包含睫狀肌麻痺劑,或可僅浸潤溶液20包含睫狀肌麻痺劑,或者可隱形眼鏡10與浸潤溶液20同時包含睫狀肌麻痺劑。藉此,本發明的隱形眼鏡10可改善使用睫狀肌麻痺劑時,因睫狀肌麻痺劑造成瞳孔放大而導致周邊像差與影像模糊的問題,由於睫狀肌麻痺劑的作用會使瞳孔放大至原一般瞳孔大小的2~4倍之多,瞳孔放大使得周邊區域過多光線進入到眼內,其明顯干擾造並於周邊產生像差,因此本發明的隱形眼鏡10可阻擋過多光線進入並兼顧充足光通量以避免嚴重畏光問題,進一步有效消除周邊像差,確保持視野範圍內影像的清晰度和銳利度。At least one of the
具體來說,可於製備隱形眼鏡10的組成物中加入睫狀肌麻痺劑,而使最終成形的隱形眼鏡10內含睫狀肌麻痺劑,藉此,配戴隱形眼鏡10時可緩慢釋放出睫狀肌麻痺劑,有助於延緩近視效果,簡化治療程序使患者藉由簡單配戴隱形眼鏡10即具有視力控制功能。或者,可於市面上浸泡、保存隱形眼鏡的溶液加入睫狀肌麻痺劑,而使浸潤溶液20中包含睫狀肌麻痺劑,藉此,睫狀肌麻痺劑可於隱形眼鏡10配戴時即可產生作用,有效發揮立即性效果同時具有簡化治療程序功能。睫狀肌麻痺劑於隱形眼鏡10或於浸潤溶液20中的重量百分比濃度為ConA,其可滿足下列條件:0% < ConA ≤ 1%。或者,其可滿足下列條件:0% < ConA ≤ 0.5%。或者,其可滿足下列條件:0% < ConA ≤ 0.25%。或者,其可滿足下列條件:0% < ConA ≤ 0.1%。或者,其可滿足下列條件:0% < ConA ≤ 0.05%。或者,其可滿足下列條件:0% < ConA ≤ 0.01%。Specifically, a ciliary muscle anesthetic may be added to the composition for preparing the
根據上述說明,以下提出具體實施例並配合圖式予以詳細說明。Based on the above description, specific embodiments are presented below and described in detail with reference to the drawings.
<實施例1><Example 1>
第3圖是繪示依照本發明實施例1的一種隱形眼鏡100的示意圖。第3圖中,隱形眼鏡100包含光學區110以及阻光環型區120,阻光環型區120環繞隱形眼鏡100的中心點O設置,且阻光環型區120的內周緣120A為圓形。光學區110為虛線所圍起的區域,實施例1中,光學區110與阻光環型區120有部分重疊。FIG. 3 is a schematic diagram showing a contact lens 100 according to Embodiment 1 of the present invention. In FIG. 3, the contact lens 100 includes an optical zone 110 and a light-blocking annular zone 120. The light-blocking annular zone 120 is disposed around the center point O of the contact lens 100, and the inner periphery 120A of the light-blocking annular zone 120 is circular. The optical zone 110 is the area enclosed by the dotted line. In Embodiment 1, the optical zone 110 and the light-blocking annular zone 120 partially overlap.
實施例1中,阻光環型區120的最小直徑為CDmin,阻光環型區120的最大直徑為CDmax,光學區110的最大直徑為OD,隱形眼鏡100的最大直徑為D,隱形眼鏡100的基弧為BC(可參考第1A圖),實施例1的CDmin、CDmax、OD、D、CDmin/D、CDmax/D、CDmax-CDmin、CDmin/OD、BC等參數的數值記錄於表一中。
隱形眼鏡100的材質為水膠,製備水膠的組成物包含以下單體:甲基丙烯酸羥乙酯、甲基丙烯酸、2-甲基-2-丙烯酸-2,3-二羥基丙酯以及N-乙烯基-2-吡咯酮。隱形眼鏡100為單焦點隱形眼鏡。The contact lens 100 is made of hydrogel, and the composition for preparing the hydrogel includes the following monomers: hydroxyethyl methacrylate, methacrylic acid, 2-methyl-2-acrylate-2,3-dihydroxypropyl ester, and N-vinyl-2-pyrrolidone. The contact lens 100 is a single-focus contact lens.
阻光環型區120於可見光的平均穿透率為Tavg,其以波長範圍200nm~400nm的光照射10秒時間前後數值如表二所示。
<實施例2><Example 2>
第4圖是繪示依照本發明實施例2的一種隱形眼鏡200的示意圖。第4圖中,隱形眼鏡200包含光學區210以及阻光環型區220,阻光環型區220環繞隱形眼鏡200的中心點O設置,且阻光環型區220的內周緣220A為圓形。具體來說,阻光環型區220包含四個不相連的阻光部,分別為第一阻光部221、第二阻光部222、第三阻光部223以及第四阻光部224。光學區210為虛線所圍起的區域,實施例2中,光學區210與阻光環型區220有部分重疊。FIG. 4 is a schematic diagram of a contact lens 200 according to Embodiment 2 of the present invention. In FIG. 4, the contact lens 200 includes an optical zone 210 and a light-blocking annular zone 220. The light-blocking annular zone 220 is arranged around the center point O of the contact lens 200, and the inner periphery 220A of the light-blocking annular zone 220 is circular. Specifically, the light-blocking annular zone 220 includes four unconnected light-blocking portions, namely a first light-blocking portion 221, a second light-blocking portion 222, a third light-blocking portion 223, and a fourth light-blocking portion 224. The optical zone 210 is the area enclosed by the dotted line. In Embodiment 2, the optical zone 210 and the light-blocking annular zone 220 partially overlap.
實施例2的CDmin、CDmax、OD、D、CDmin/D、CDmax/D、CDmax-CDmin、CDmin/OD、BC等參數的數值記錄於表三中,前述參數的定義請參照實施例1。
隱形眼鏡200的材質為水膠,製備水膠的組成物包含以下單體:甲基丙烯酸羥乙酯、甲基丙烯酸以及2-甲基-2-丙烯酸-2,3-二羥基丙酯。隱形眼鏡200為單焦點隱形眼鏡。The contact lens 200 is made of hydrogel, and the composition for preparing the hydrogel includes the following monomers: hydroxyethyl methacrylate, methacrylic acid, and 2-methyl-2-acrylate-2,3-dihydroxypropyl ester. The contact lens 200 is a single-focus contact lens.
阻光環型區220於可見光的平均穿透率為Tavg,其以波長範圍200nm~400nm的光照射10秒時間前後數值如表四所示。
此外,在實施例2中,由內到外具有第一阻光部221、第二阻光部222、第三阻光部223以及第四阻光部224於可見光的平均穿透率可不相同,在實施例2中,第一阻光部221於可見光的平均穿透率為Tavg1,第二阻光部222於可見光的平均穿透率為Tavg2,第三阻光部223於可見光的平均穿透率為Tavg3,第四阻光部224於可見光的平均穿透率為Tavg4,其中,Tavg1 > Tavg2 > Tavg3 > Tavg4。表四中,Tavg數值為不同阻光部(221-224)中,可獲得的最小平均穿透率,即表示該阻光部(221-224其中至少一者)具有最佳的阻擋光線效果,換句話說,實施例2中,Tavg = Tavg4。In addition, in Embodiment 2, the average transmittances of the first light-blocking portion 221, the second light-blocking portion 222, the third light-blocking portion 223 and the fourth light-blocking portion 224 from the inside to the outside in visible light may be different. In Embodiment 2, the average transmittance of the first light-blocking portion 221 in visible light is Tavg1, the average transmittance of the second light-blocking portion 222 in visible light is Tavg2, the average transmittance of the third light-blocking portion 223 in visible light is Tavg3, and the average transmittance of the fourth light-blocking portion 224 in visible light is Tavg4, wherein Tavg1 > Tavg2 > Tavg3 > Tavg4. In Table 4, the Tavg value is the minimum average transmittance that can be obtained in different light-blocking portions (221-224), which means that the light-blocking portion (at least one of 221-224) has the best light-blocking effect. In other words, in Example 2, Tavg = Tavg4.
<實施例3><Example 3>
第5圖是繪示依照本發明實施例3的一種隱形眼鏡300的示意圖。第5圖中,隱形眼鏡300包含光學區310以及阻光環型區320,阻光環型區320環繞隱形眼鏡300的中心點O設置,且阻光環型區320的內周緣320A為圓形。光學區310為虛線所圍起的區域,實施例3中,光學區310與阻光環型區320有部分重疊。FIG. 5 is a schematic diagram showing a contact lens 300 according to Embodiment 3 of the present invention. In FIG. 5, the contact lens 300 includes an optical zone 310 and a light-blocking annular zone 320. The light-blocking annular zone 320 is disposed around the center point O of the contact lens 300, and the inner periphery 320A of the light-blocking annular zone 320 is circular. The optical zone 310 is the area enclosed by the dotted line. In Embodiment 3, the optical zone 310 and the light-blocking annular zone 320 partially overlap.
實施例3的CDmin、CDmax、OD、D、CDmin/D、CDmax/D、CDmax-CDmin、CDmin/OD、BC等參數的數值記錄於表五中,前述參數的定義請參照實施例1。
隱形眼鏡300的材質為水膠,製備水膠的組成物包含以下單體:甲基丙烯酸羥乙酯以及甲基丙烯酸。隱形眼鏡300為多焦點隱形眼鏡。The contact lens 300 is made of hydrogel, and the composition of the hydrogel includes the following monomers: hydroxyethyl methacrylate and methacrylic acid. The contact lens 300 is a multifocal contact lens.
阻光環型區320於可見光的平均穿透率為Tavg,其以波長範圍200nm~400nm的光照射10秒時間前後數值如表六所示。
<實施例4><Example 4>
第6圖是繪示依照本發明實施例4的一種隱形眼鏡400的示意圖。第6圖中,隱形眼鏡400包含光學區410以及阻光環型區420,阻光環型區420環繞隱形眼鏡400的中心點O設置,且阻光環型區420的內周緣420A為圓形。光學區410為虛線所圍起的區域,實施例4中,光學區410與阻光環型區420有部分重疊。FIG. 6 is a schematic diagram showing a
實施例4的CDmin、CDmax、OD、D、CDmin/D、CDmax/D、CDmax-CDmin、CDmin/OD、BC等參數的數值記錄於表七中,前述參數的定義請參照實施例1。
隱形眼鏡400的材質為水膠,製備水膠的組成物包含以下單體:甲基丙烯酸羥乙酯以及2-甲基-2-丙烯酸-2,3-二羥基丙酯。隱形眼鏡400為多焦點隱形眼鏡,且隱形眼鏡400包含睫狀肌麻痺劑。The
阻光環型區420於可見光的平均穿透率為Tavg,其以波長範圍200nm~400nm的光照射10秒時間前後數值如表八所示。
<實施例5><Example 5>
第7圖是繪示依照本發明實施例5的一種隱形眼鏡500的示意圖。第7圖中,隱形眼鏡500包含光學區510以及阻光環型區520,阻光環型區520環繞隱形眼鏡500的中心點O設置,且阻光環型區520的內周緣520A為十邊形。光學區510為虛線所圍起的區域,實施例5中,光學區510與阻光環型區520有部分重疊。FIG. 7 is a schematic diagram showing a contact lens 500 according to Embodiment 5 of the present invention. In FIG. 7, the contact lens 500 includes an optical zone 510 and a light-blocking annular zone 520. The light-blocking annular zone 520 is disposed around the center point O of the contact lens 500, and the inner periphery 520A of the light-blocking annular zone 520 is a decagon. The optical zone 510 is the area enclosed by the dotted line. In Embodiment 5, the optical zone 510 and the light-blocking annular zone 520 partially overlap.
實施例5的CDmin、CDmax、OD、D、CDmin/D、CDmax/D、CDmax-CDmin、CDmin/OD、BC等參數的數值記錄於表九中,前述參數的定義請參照實施例1。
隱形眼鏡500的材質為水膠,製備水膠的組成物包含以下單體:甲基丙烯酸羥乙酯以及N-乙烯基-2-吡咯酮。隱形眼鏡500為單焦點隱形眼鏡。The material of the contact lens 500 is hydrogel, and the composition for preparing the hydrogel includes the following monomers: hydroxyethyl methacrylate and N-vinyl-2-pyrrolidone. The contact lens 500 is a single-focus contact lens.
阻光環型區520於可見光的平均穿透率為Tavg,其以波長範圍200nm~400nm的光照射10秒時間前後數值如表十所示。
<實施例6><Example 6>
第8圖是繪示依照本發明實施例6的一種隱形眼鏡600的示意圖。第8圖中,隱形眼鏡600包含光學區610以及阻光環型區620,阻光環型區620環繞隱形眼鏡600的中心點O設置,且阻光環型區620的內周緣620A為六邊形。光學區610為虛線所圍起的區域,實施例6中,光學區610有部分與阻光環型區620重疊。FIG. 8 is a schematic diagram showing a contact lens 600 according to Embodiment 6 of the present invention. In FIG. 8 , the contact lens 600 includes an optical zone 610 and a light-blocking annular zone 620. The light-blocking annular zone 620 is disposed around the center point O of the contact lens 600, and the inner periphery 620A of the light-blocking annular zone 620 is a hexagon. The optical zone 610 is the area enclosed by the dotted line. In Embodiment 6, the optical zone 610 partially overlaps with the light-blocking annular zone 620.
實施例6的CDmin、CDmax、OD、D、CDmin/D、CDmax/D、CDmax-CDmin、CDmin/OD、BC等參數的數值記錄於表十一中,前述參數的定義請參照實施例1。
隱形眼鏡600的材質為水膠,製備水膠的組成物包含以下單體:甲基丙烯酸羥乙酯、2-甲基-2-丙烯酸-2,3-二羥基丙酯以及N-乙烯基-2-吡咯酮。隱形眼鏡600為單焦點隱形眼鏡,且隱形眼鏡600包含睫狀肌麻痺劑。The contact lens 600 is made of hydrogel, and the composition for preparing the hydrogel includes the following monomers: hydroxyethyl methacrylate, 2-methyl-2-acrylate-2,3-dihydroxypropyl ester, and N-vinyl-2-pyrrolidone. The contact lens 600 is a single-focus contact lens, and the contact lens 600 includes a ciliary muscle anesthetic.
阻光環型區620包含光致變色材料,實施例6使用的光致變色材料為1′,3′-二氫-1′,3′,3′-三甲基-6-硝基螺[2H-1-苯并吡喃-2,2′-(2H)-吲哚]。阻光環型區620於可見光的平均穿透率為Tavg,其以波長範圍200nm~400nm的光照射10秒時間前後數值如表十二所示。
<實施例7><Example 7>
第9圖是繪示依照本發明實施例7的一種隱形眼鏡700的示意圖。第9圖中,隱形眼鏡700包含光學區710以及阻光環型區720,阻光環型區720環繞隱形眼鏡700的中心點O設置,且阻光環型區720的內周緣720A為四邊形。具體來說,阻光環型區720包含三個阻光部,分別為第一阻光部721、第二阻光部722以及第三阻光部723。光學區710為虛線所圍起的區域,實施例7中,光學區710有部分與阻光環型區720重疊。FIG. 9 is a schematic diagram of a contact lens 700 according to Embodiment 7 of the present invention. In FIG. 9, the contact lens 700 includes an optical zone 710 and a light-blocking annular zone 720. The light-blocking annular zone 720 is arranged around the center point O of the contact lens 700, and the inner periphery 720A of the light-blocking annular zone 720 is a quadrilateral. Specifically, the light-blocking annular zone 720 includes three light-blocking portions, namely a first light-blocking portion 721, a second light-blocking portion 722, and a third light-blocking portion 723. The optical zone 710 is the area enclosed by the dotted line. In Embodiment 7, the optical zone 710 partially overlaps with the light-blocking annular zone 720.
實施例7的CDmin、CDmax、OD、D、CDmin/D、CDmax/D、CDmax-CDmin、CDmin/OD、BC等參數的數值記錄於表十三中,前述參數的定義請參照實施例1。
隱形眼鏡700的材質為水膠,製備水膠的組成物包含以下單體:甲基丙烯酸羥乙酯、甲基丙烯酸以及N-乙烯基-2-吡咯酮。隱形眼鏡700為多焦點隱形眼鏡。The material of the contact lens 700 is hydrogel, and the composition of the hydrogel includes the following monomers: hydroxyethyl methacrylate, methacrylic acid, and N-vinyl-2-pyrrolidone. The contact lens 700 is a multifocal contact lens.
阻光環型區720包含光致變色材料,實施例7使用的光致變色材料為1,3-二氫-1,3,3-三甲基螺[2H-吲哚-2,3′-[3H]萘并[2,1-b][1,4]嗪]。阻光環型區720於可見光的平均穿透率為Tavg,其以波長範圍200nm~400nm的光照射10秒時間前後數值如表十四所示。
此外,在實施例7中,由內到外具有第一阻光部721、第二阻光部722以及第三阻光部723於可見光的平均穿透率可不相同,在實施例7中,第一阻光部721於可見光的平均穿透率為Tavg1,第二阻光部722於可見光的平均穿透率為Tavg2,第三阻光部723於可見光的平均穿透率為Tavg3,其中,Tavg1 > Tavg2 且 Tavg3 > Tavg2,Tavg1可等於Tavg3,亦可為不相等。表十四中,Tavg數值為不同阻光部(721-723)中,可獲得的最小平均穿透率,即表示該阻光部(721-723其中至少一者)具有最佳的阻擋光線效果,換句話說,實施例7中,Tavg = Tavg2。In addition, in Embodiment 7, the average transmittance of the first light-blocking portion 721, the second light-blocking portion 722, and the third light-blocking portion 723 from the inside to the outside in visible light may be different. In Embodiment 7, the average transmittance of the first light-blocking portion 721 in visible light is Tavg1, the average transmittance of the second light-blocking portion 722 in visible light is Tavg2, and the average transmittance of the third light-blocking portion 723 in visible light is Tavg3, wherein Tavg1>Tavg2 and Tavg3>Tavg2, Tavg1 may be equal to Tavg3, or may be unequal. In Table 14, the Tavg value is the minimum average transmittance that can be obtained in different light-blocking portions (721-723), which means that the light-blocking portion (at least one of 721-723) has the best light-blocking effect. In other words, in Embodiment 7, Tavg = Tavg2.
<實施例8><Example 8>
第10圖是繪示依照本發明實施例8的一種隱形眼鏡800的示意圖。第10圖中,隱形眼鏡800包含光學區810以及阻光環型區820,阻光環型區820環繞隱形眼鏡800的中心點O設置,且阻光環型區820的內周緣820A為八邊形。具體來說,阻光環型區820包含二個阻光部,分別為第一阻光部821以及第二阻光部822。光學區810為虛線所圍起的區域,實施例8中,光學區810有部分與阻光環型區820重疊。FIG. 10 is a schematic diagram showing a contact lens 800 according to Embodiment 8 of the present invention. In FIG. 10 , the contact lens 800 includes an optical zone 810 and a light-blocking annular zone 820. The light-blocking annular zone 820 is disposed around the center point O of the contact lens 800, and the inner periphery 820A of the light-blocking annular zone 820 is an octagon. Specifically, the light-blocking annular zone 820 includes two light-blocking portions, namely a first light-blocking portion 821 and a second light-blocking portion 822. The optical zone 810 is the area enclosed by the dotted line. In Embodiment 8, the optical zone 810 partially overlaps with the light-blocking annular zone 820.
實施例8的CDmin、CDmax、OD、D、CDmin/D、CDmax/D、CDmax-CDmin、CDmin/OD、BC等參數的數值記錄於表十五中,前述參數的定義請參照實施例1。
隱形眼鏡800的材質為矽水膠,製備矽水膠的組成物包含以下單體:甲基丙烯酸羥乙酯、N-乙烯基-2-吡咯酮、N,N-二甲基丙烯醯胺、3-乙醯氧基-2-羥基丙氧基丙基封端的聚二甲基矽氧烷以及甲基丙烯酸甲酯。隱形眼鏡800為多焦點隱形眼鏡。Contact lens 800 is made of silicone hydrogel, and the composition of silicone hydrogel includes the following monomers: hydroxyethyl methacrylate, N-vinyl-2-pyrrolidone, N,N-dimethylacrylamide, 3-acetoxy-2-hydroxypropoxypropyl terminated polydimethylsiloxane and methyl methacrylate. Contact lens 800 is a multifocal contact lens.
阻光環型區820包含光致變色材料,實施例8使用的光致變色材料為羥基-4-甲基-2H-萘并(1,2-B)吡喃-2-酮。阻光環型區820於可見光的平均穿透率為Tavg,其以波長範圍200nm~400nm的光照射10秒時間前後數值如表十六所示。
此外,在實施例8中,由內到外具有第一阻光部821以及第二阻光部822於可見光的平均穿透率可不相同,在實施例8中,第一阻光部821於可見光的平均穿透率為Tavg1,第二阻光部822於可見光的平均穿透率為Tavg2,其中,Tavg1 < Tavg2。表十六中,Tavg數值為不同阻光部(821-822)中,可獲得的最小平均穿透率,即表示該阻光部(821-822其中至少一者)具有最佳的阻擋光線效果,換句話說,實施例8中,Tavg = Tavg1。In addition, in the eighth embodiment, the average transmittance of the first light-blocking portion 821 and the second light-blocking portion 822 from the inside to the outside in visible light may be different. In the eighth embodiment, the average transmittance of the first light-blocking portion 821 in visible light is Tavg1, and the average transmittance of the second light-blocking portion 822 in visible light is Tavg2, wherein Tavg1 < Tavg2. In Table 16, the value of Tavg is the minimum average transmittance that can be obtained in different light-blocking portions (821-822), which means that the light-blocking portion (at least one of 821-822) has the best light-blocking effect. In other words, in the eighth embodiment, Tavg = Tavg1.
<實施例9><Example 9>
第11圖是繪示依照本發明實施例9的一種隱形眼鏡900的示意圖。第11圖中,隱形眼鏡900包含光學區910以及阻光環型區920,阻光環型區920環繞隱形眼鏡900的中心點O設置,且阻光環型區920的內周緣920A為圓形。光學區910為虛線所圍起的區域,實施例9中,光學區910有部分與阻光環型區920重疊。FIG. 11 is a schematic diagram showing a contact lens 900 according to Embodiment 9 of the present invention. In FIG. 11 , the contact lens 900 includes an optical zone 910 and a light-blocking annular zone 920. The light-blocking annular zone 920 is disposed around the center point O of the contact lens 900, and the inner periphery 920A of the light-blocking annular zone 920 is circular. The optical zone 910 is the area enclosed by the dotted line. In Embodiment 9, the optical zone 910 partially overlaps with the light-blocking annular zone 920.
實施例9的CDmin、CDmax、OD、D、CDmin/D、CDmax/D、CDmax-CDmin、CDmin/OD、BC等參數的數值記錄於表十七中,前述參數的定義請參照實施例1。
隱形眼鏡900的材質為矽水膠,製備矽水膠的組成物包含以下單體:甲基丙烯酸羥乙酯、甲基丙烯醯氧丙基三(三甲基矽氧烷基)矽烷、(3-甲基丙烯醯氧基-2-羥基丙氧基)丙基双(三甲基矽氧基)甲基以及甲基丙烯酸甲酯。隱形眼鏡900為單焦點隱形眼鏡。Contact lens 900 is made of silicone hydrogel, and the composition of silicone hydrogel includes the following monomers: hydroxyethyl methacrylate, methacryloyloxypropyl tris(trimethylsiloxy)silane, (3-methacryloyloxy-2-hydroxypropoxy)propyl bis(trimethylsiloxy)methyl and methyl methacrylate. Contact lens 900 is a single-focus contact lens.
阻光環型區920包含光致變色材料,實施例9使用的光致變色材料為(E)-亞苄基(二苯亞甲基)琥珀酸酐。阻光環型區920於可見光的平均穿透率為Tavg,其以波長範圍200nm~400nm的光照射10秒時間前後數值如表十八所示。
<實施例10><Example 10>
第12圖是繪示依照本發明實施例10的一種隱形眼鏡1000的示意圖。第12圖中,隱形眼鏡1000包含光學區1010以及阻光環型區1020,阻光環型區1020環繞隱形眼鏡1000的中心點O設置,且阻光環型區1020的內周緣1020A為圓形。光學區1010為虛線所圍起的區域,實施例10中,光學區1010與阻光環型區1020錯開。FIG. 12 is a schematic diagram showing a contact lens 1000 according to
實施例10的CDmin、CDmax、OD、D、CDmin/D、CDmax/D、CDmax-CDmin、CDmin/OD、BC等參數的數值記錄於表十九中,前述參數的定義請參照實施例1。
隱形眼鏡1000的材質為矽水膠,製備矽水膠的組成物包含以下單體:甲基丙烯酸羥乙酯、N-乙烯基-2-吡咯酮、N,N-二甲基丙烯醯胺、甲基丙烯醯氧丙基三(三甲基矽氧烷基)矽烷、3-乙醯氧基-2-羥基丙氧基丙基封端的聚二甲基矽氧烷以及甲基丙烯酸甲酯。隱形眼鏡1000為單焦點隱形眼鏡,且隱形眼鏡1000包含睫狀肌麻痺劑。The material of the contact lens 1000 is silicone hydrogel, and the composition for preparing the silicone hydrogel includes the following monomers: hydroxyethyl methacrylate, N-vinyl-2-pyrrolidone, N,N-dimethylacrylamide, methacryloyloxypropyl tris(trimethylsiloxyalkyl)silane, 3-acetoxy-2-hydroxypropoxypropyl-terminated polydimethylsiloxane, and methyl methacrylate. The contact lens 1000 is a single-focus contact lens, and the contact lens 1000 includes a ciliary muscle anesthetic.
阻光環型區1020包含光致變色材料,實施例10使用的光致變色材料為9,10-二氫菲。阻光環型區1020於可見光的平均穿透率為Tavg,其以波長範圍200nm~400nm的光照射10秒時間前後數值如表二十所示。
<實施例11><Example 11>
第13圖是繪示依照本發明實施例11的一種隱形眼鏡1100的示意圖。第13圖中,隱形眼鏡1100包含光學區1110以及阻光環型區1120,阻光環型區1120環繞隱形眼鏡1100的中心點O設置,且阻光環型區1120的內周緣1120A為圓形。光學區1110為虛線所圍起的區域,實施例11中,光學區1110與阻光環型區1120錯開。FIG. 13 is a schematic diagram showing a contact lens 1100 according to Embodiment 11 of the present invention. In FIG. 13 , the contact lens 1100 includes an optical zone 1110 and a light-blocking annular zone 1120. The light-blocking annular zone 1120 is disposed around the center point O of the contact lens 1100, and the inner periphery 1120A of the light-blocking annular zone 1120 is circular. The optical zone 1110 is the area enclosed by the dotted line. In Embodiment 11, the optical zone 1110 and the light-blocking annular zone 1120 are staggered.
實施例11的CDmin、CDmax、OD、D、CDmin/D、CDmax/D、CDmax-CDmin、CDmin/OD、BC等參數的數值記錄於表二十一中,前述參數的定義請參照實施例1。
隱形眼鏡1100的材質為矽水膠,製備矽水膠的組成物包含以下單體:甲基丙烯酸羥乙酯、N,N-二甲基丙烯醯胺以及(3-甲基丙烯醯氧基-2-羥基丙氧基)丙基双(三甲基矽氧基)甲基。隱形眼鏡1100為多焦點隱形眼鏡,且隱形眼鏡1100包含睫狀肌麻痺劑。The material of the contact lens 1100 is silicone hydrogel, and the composition of the silicone hydrogel includes the following monomers: hydroxyethyl methacrylate, N,N-dimethylacrylamide, and (3-methacryloyloxy-2-hydroxypropoxy)propylbis(trimethylsiloxy)methyl. The contact lens 1100 is a multifocal contact lens, and the contact lens 1100 includes a ciliary muscle anesthetic.
阻光環型區1120包含光致變色材料,實施例11使用的光致變色材料包含1,3-二氫-1,3,3-三甲基螺[2H-吲哚-2,3′-[3H]萘并[2,1-b][1,4]嗪]以及(E)-亞苄基(二苯亞甲基)琥珀酸酐。阻光環型區1120於可見光的平均穿透率為Tavg,其以波長範圍200nm~400nm的光照射10秒時間前後數值如表二十二所示。
<實施例12><Example 12>
第14圖是繪示依照本發明實施例12的一種隱形眼鏡1200的示意圖。第14圖中,隱形眼鏡1200包含光學區1210以及阻光環型區1220,阻光環型區1220環繞隱形眼鏡1200的中心點O設置,且阻光環型區1220的內周緣1220A為圓形。光學區1210為虛線所圍起的區域,實施例12中,光學區1210有部分與阻光環型區1220重疊。FIG. 14 is a schematic diagram of a contact lens 1200 according to Embodiment 12 of the present invention. In FIG. 14, the contact lens 1200 includes an optical zone 1210 and a light-blocking annular zone 1220. The light-blocking annular zone 1220 is disposed around the center point O of the contact lens 1200, and the inner periphery 1220A of the light-blocking annular zone 1220 is circular. The optical zone 1210 is the area enclosed by the dotted line. In Embodiment 12, the optical zone 1210 partially overlaps with the light-blocking annular zone 1220.
實施例12的CDmin、CDmax、OD、D、CDmin/D、CDmax/D、CDmax-CDmin、CDmin/OD、BC等參數的數值記錄於表二十三中,前述參數的定義請參照實施例1。
隱形眼鏡1200的材質為矽水膠,製備矽水膠的組成物包含以下單體:甲基丙烯酸羥乙酯、2-甲基-2-丙烯酸-2,3-二羥基丙酯、N-乙烯基-2-吡咯酮、N,N-二甲基丙烯醯胺、甲基丙烯醯氧丙基三(三甲基矽氧烷基)矽烷、(3-甲基丙烯醯氧基-2-羥基丙氧基)丙基双(三甲基矽氧基)甲基、3-乙醯氧基-2-羥基丙氧基丙基封端的聚二甲基矽氧烷以及甲基丙烯酸甲酯。隱形眼鏡1200為多焦點隱形眼鏡。The material of the contact lens 1200 is silicone hydrogel, and the composition of the silicone hydrogel includes the following monomers: hydroxyethyl methacrylate, 2-methyl-2-acrylate-2,3-dihydroxypropyl ester, N-vinyl-2-pyrrolidone, N,N-dimethylacrylamide, methacryloxypropyl tris(trimethylsiloxyalkyl)silane, (3-methacryloxy-2-hydroxypropoxy)propyl bis(trimethylsiloxy)methyl, 3-acetoxy-2-hydroxypropoxypropyl terminated polydimethylsiloxane, and methyl methacrylate. The contact lens 1200 is a multifocal contact lens.
阻光環型區1220包含光致變色材料,實施例12使用的光致變色材料包含1′,3′-二氫-1′,3′,3′-三甲基-6-硝基螺[2H-1-苯并吡喃-2,2′-(2H)-吲哚]、羥基-4-甲基-2H-萘并(1,2-B)吡喃-2-酮以及9,10-二氫菲。阻光環型區1220於可見光的平均穿透率為Tavg,其以波長範圍200nm~400nm的光照射10秒時間前後數值如表二十四所示。
<實施例13><Example 13>
第15圖是繪示依照本發明實施例13的一種隱形眼鏡1300的示意圖。第15圖中,隱形眼鏡1300包含光學區1310以及阻光環型區1320,阻光環型區1320環繞隱形眼鏡1300的中心點O設置,且阻光環型區1320的內周緣1320A為圓形。光學區1310為虛線所圍起的區域,實施例13中,光學區1310與阻光環型區1320錯開。在實施例13中,阻光環型區1320僅包含一個阻光部(未另標號),且阻光部包含複數個微阻光部1320a,此些微阻光部1320a呈輻射狀排列方式,且此些微阻光部1320a於可見光的平均穿透率可為漸層式變化,意即不同微阻光部1320a可沿著順時針方向或逆時針方向具有不同的顏色深淺變化,在實施例13中,為由12點鐘的位置沿著順時針方向是淺漸深、深漸淺、淺漸深、再深漸淺的變化,在其他實施例中,可依實際需求安排其他的顏色深淺變化。FIG. 15 is a schematic diagram showing a contact lens 1300 according to Embodiment 13 of the present invention. In FIG. 15 , the contact lens 1300 includes an optical zone 1310 and a light-blocking annular zone 1320. The light-blocking annular zone 1320 is disposed around the center point O of the contact lens 1300, and the inner periphery 1320A of the light-blocking annular zone 1320 is circular. The optical zone 1310 is the area enclosed by the dotted line. In Embodiment 13, the optical zone 1310 and the light-blocking annular zone 1320 are staggered. In embodiment 13, the light-blocking annular area 1320 includes only one light-blocking portion (not separately labeled), and the light-blocking portion includes a plurality of micro light-blocking portions 1320a, and these micro light-blocking portions 1320a are arranged in a radial shape, and the average transmittance of these micro light-blocking portions 1320a in visible light can be gradually changed, that is, different micro light-blocking portions 1320a can have different color depth changes along the clockwise direction or the counterclockwise direction. In embodiment 13, the color depth changes from the 12 o'clock position along the clockwise direction are shallow gradual, deep gradual, shallow gradual, and deep gradual again. In other embodiments, other color depth changes can be arranged according to actual needs.
依據本發明的隱形眼鏡,光學區是指隱形眼鏡基弧所及的範圍,即具有屈光力的區域。According to the contact lens of the present invention, the optical zone refers to the range covered by the base curve of the contact lens, that is, the area with refractive power.
依據本發明的隱形眼鏡,參數設計皆未限定僅使用於隱形眼鏡的前表面或後表面,可任選其中一表面或者前、後表面同時設計。According to the contact lens of the present invention, the parameter design is not limited to be used only on the front surface or the back surface of the contact lens, and can be designed on either surface or both the front and back surfaces.
依據本發明的隱形眼鏡,阻光環型區可藉由將阻光材料以轉印、印刷或塗佈等製程方法,形成於隱形眼鏡上,或者可將阻光材料混摻於製備阻光環型區的組成物中,使阻光材料分散於阻光環型區整體,此外,可藉由選擇並調整阻光材料的濃度與顏色,而製作成具阻擋光線效果的隱形眼鏡,依不同需求可製作出所需不同程度的透光度以有效減低可見光的平均穿透率,阻光材料可使用行政院衛生署食品藥物管理局(Taiwan Food and Drug Administration,TFDA)、美國食品藥物管理局(Food and Drug Administration,FDA)或任何國家食品藥物管理局核准可用於醫療器材的色彩材料。According to the contact lens of the present invention, the light-blocking annular region can be formed on the contact lens by transferring, printing or coating the light-blocking material, or the light-blocking material can be mixed into the composition for preparing the light-blocking annular region so that the light-blocking material is dispersed in the entire light-blocking annular region. In addition, the light-blocking contact lens can be manufactured by selecting and adjusting the concentration and color of the light-blocking material. The light-blocking material can be manufactured to have different degrees of light transmittance according to different needs to effectively reduce the average transmittance of visible light. The light-blocking material can be a color material approved for medical devices by the Taiwan Food and Drug Administration (TFDA), the U.S. Food and Drug Administration (FDA) or any national food and drug administration.
依據本發明的隱形眼鏡,光致變材料可藉由吸收光線(如藍光、UV等)而轉變為低可見光穿透的顏色,有效降低甚至阻擋可見光穿透,當光線來源消失後,光致變材料又可恢復為原有可見光的穿透率,其轉變為可逆反應。According to the contact lenses of the present invention, the photovariable material can be transformed into a color with low visible light transmittance by absorbing light (such as blue light, UV, etc.), effectively reducing or even blocking visible light transmission. When the light source disappears, the photovariable material can be restored to its original visible light transmittance, and the transformation is a reversible reaction.
依據本發明的隱形眼鏡,睫狀肌麻痺劑包含但不限於阿托品(Atropine;(3-endo)-8-methyl-8- azabicyclo[3.2.1]oct-3-yl tropate)、托吡卡胺(Tropicamide;N-ethyl-3-hydroxy-2-phenyl-N- (4-pyridinylmethyl)propanamide)、環戊醇胺酯(Cyclopentolate;2-(dimethylamino)ethyl (1-hydroxycyclopentyl)(phenyl)acetate)、后馬托品(Homatropine;(3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl hydroxy(phenyl)acetate)、東莨菪鹼(Scopolamine;(1R,2R,4S,5S,7s)-9-methyl-3-oxa-9- azatricyclo[3.3.1.02,4 ]non-7-yl(2S)-3-hydroxy-2-phenylpropanoate)與尤卡托品(Eucatropine;1,2,2,6-tetramethyl-4-piperidinyl hydroxyl (phenyl)acetate)及前述物質的鹽類。睫狀肌麻痺劑又稱為作散瞳劑,並屬於副交感神經阻斷劑,亦即為一種非選擇性的M型蕈毒鹼受器阻斷藥,其可藉由阻斷蕈毒鹼受器而使控制瞳孔的睫狀肌麻痺與鬆弛,進而使得瞳孔放大。According to the contact lens of the present invention, the ciliary muscle paralytic agent includes but is not limited to atropine ((3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl tropate), tropicamide (N-ethyl-3-hydroxy-2-phenyl-N- (4-pyridinylmethyl)propanamide), cyclopentolate (2-(dimethylamino)ethyl (1-hydroxycyclopentyl)(phenyl)acetate), homatropine ((3-endo)-8-methyl-8-azabicyclo[3.2.1]oct-3-yl hydroxy(phenyl)acetate), scopolamine ((1R,2R,4S,5S,7s)-9-methyl-3-oxa-9- azatricyclo[3.3.1.0 2,4 ]non-7-yl(2S)-3-hydroxy-2-phenylpropanoate) and eucatropine (1,2,2,6-tetramethyl-4-piperidinyl hydroxyl (phenyl)acetate) and their salts. Ciliary muscle anesthetics are also called mydriatics and belong to the class of parasympathetic nerve blockers, that is, they are non-selective M-type muscarinic receptor blockers that can paralyze and relax the ciliary muscles that control the pupil by blocking muscarinic receptors, thereby dilating the pupil.
雖然本發明已以實施方式揭露如上,然其並非用以限定本發明,任何熟習此技藝者,在不脫離本發明的精神和範圍內,當可作各種的更動與潤飾,因此本發明的保護範圍當視後附的申請專利範圍所界定者為準。Although the present invention has been disclosed in the above embodiments, it is not intended to limit the present invention. Anyone skilled in the art can make various changes and modifications without departing from the spirit and scope of the present invention. Therefore, the scope of protection of the present invention shall be determined by the scope of the attached patent application.
10,100,200,300,400,500,600,700,800,900,1000,1100,1200,1300:隱形眼鏡
11,110,210,310,410,510,610,710,810,910,1010,1110,1210,1310:光學區
12,120,220,320,420,520,620,720,820,920,1020,1120,1220,1320:阻光環型區
221,721,821:第一阻光部
222,722,822:第二阻光部
223,723:第三阻光部
224:第四阻光部
1320a:微阻光部
12A,120A,220A,320A,420A,520A,620A,720A,820A,920A,1020A,1120A,1220A,1320A:內周緣
O:中心點
20:浸潤溶液
30:隱形眼鏡產品
CDmin:阻光環型區的最小直徑
CDmax:阻光環型區的最大直徑
OD:光學區的最大直徑
D:隱形眼鏡的最大直徑
BC:隱形眼鏡的基弧
Tavg:阻光環型區於可見光的平均穿透率
Tavg1:第一阻光部於可見光的平均穿透率
Tavg2:第二阻光部於可見光的平均穿透率
Tavg3:第三阻光部於可見光的平均穿透率
Tavg4:第四阻光部於可見光的平均穿透率
ConA:睫狀肌麻痺劑於隱形眼鏡或於浸潤溶液中的重量百分比濃度10,100,200,300,400,500,600,700,800,900,1000,1100,1200,1300: Contact lenses
11,110,210,310,410,510,610,710,810,910,1010,1110,1210,1310: Optical area
12,120,220,320,4 20,520,620,720,820,920,1020,1120,1220,1320: light-blocking annular area
221,721,821: first light-blocking part
222,722,822: second light-blocking part
223,723: third light-blocking part
224: fourth light-blocking part
1320a: micro light-blocking
第1A圖是繪示依照本發明一實施方式的一種隱形眼鏡的示意圖; 第1B圖是繪示第1A圖中隱形眼鏡的側視示意圖; 第2圖是繪示依照本發明另一實施方式的一種隱形眼鏡產品的示意圖; 第3圖是繪示依照本發明實施例1的一種隱形眼鏡的示意圖; 第4圖是繪示依照本發明實施例2的一種隱形眼鏡的示意圖; 第5圖是繪示依照本發明實施例3的一種隱形眼鏡的示意圖; 第6圖是繪示依照本發明實施例4的一種隱形眼鏡的示意圖; 第7圖是繪示依照本發明實施例5的一種隱形眼鏡的示意圖; 第8圖是繪示依照本發明實施例6的一種隱形眼鏡的示意圖; 第9圖是繪示依照本發明實施例7的一種隱形眼鏡的示意圖; 第10圖是繪示依照本發明實施例8的一種隱形眼鏡的示意圖; 第11圖是繪示依照本發明實施例9的一種隱形眼鏡的示意圖; 第12圖是繪示依照本發明實施例10的一種隱形眼鏡的示意圖; 第13圖是繪示依照本發明實施例11的一種隱形眼鏡的示意圖; 第14圖是繪示依照本發明實施例12的一種隱形眼鏡的示意圖;以及 第15圖是繪示依照本發明實施例13的一種隱形眼鏡的示意圖。Figure 1A is a schematic diagram showing a contact lens according to one embodiment of the present invention; Figure 1B is a schematic diagram showing a side view of the contact lens in Figure 1A; Figure 2 is a schematic diagram showing a contact lens product according to another embodiment of the present invention; Figure 3 is a schematic diagram showing a contact lens according to embodiment 1 of the present invention; Figure 4 is a schematic diagram showing a contact lens according to embodiment 2 of the present invention; Figure 5 is a schematic diagram showing a contact lens according to embodiment 3 of the present invention; Figure 6 is a schematic diagram showing a contact lens according to embodiment 4 of the present invention; Figure 7 is a schematic diagram showing a contact lens according to embodiment 5 of the present invention; Figure 8 is FIG. 9 is a schematic diagram of a contact lens according to Embodiment 7 of the present invention; FIG. 10 is a schematic diagram of a contact lens according to Embodiment 8 of the present invention; FIG. 11 is a schematic diagram of a contact lens according to Embodiment 9 of the present invention; FIG. 12 is a schematic diagram of a contact lens according to Embodiment 10 of the present invention; FIG. 13 is a schematic diagram of a contact lens according to Embodiment 11 of the present invention; FIG. 14 is a schematic diagram of a contact lens according to Embodiment 12 of the present invention; and FIG. 15 is a schematic diagram of a contact lens according to Embodiment 13 of the present invention.
10:隱形眼鏡 10: Contact lenses
11:光學區 11: Optical area
12:阻光環型區 12: Light-blocking annular area
12A:內周緣 12A: Inner periphery
O:中心點 O: Center point
D:隱形眼鏡的最大直徑 D: Maximum diameter of contact lenses
OD:光學區的最大直徑 OD: Maximum diameter of the optical zone
CDmin:阻光環型區的最小直徑 CDmin: minimum diameter of the light-blocking annular area
CDmax:阻光環型區的最大直徑 CDmax: Maximum diameter of the light-blocking annular area
Claims (15)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW110130739A TWI854148B (en) | 2016-09-30 | 2016-09-30 | Contact lens and contact lens product |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
TW110130739A TWI854148B (en) | 2016-09-30 | 2016-09-30 | Contact lens and contact lens product |
Publications (2)
Publication Number | Publication Date |
---|---|
TW202144867A TW202144867A (en) | 2021-12-01 |
TWI854148B true TWI854148B (en) | 2024-09-01 |
Family
ID=80783928
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW110130739A TWI854148B (en) | 2016-09-30 | 2016-09-30 | Contact lens and contact lens product |
Country Status (1)
Country | Link |
---|---|
TW (1) | TWI854148B (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1213773C (en) * | 2000-12-07 | 2005-08-10 | 庄臣及庄臣视力保护公司 | Contact lens packaging solutions |
TWI322285B (en) * | 2004-08-19 | 2010-03-21 | Johnson & Johnson Vision Care | Tinted contact lenses with combined limbal ring and iris patterns |
TWI426318B (en) * | 2006-06-29 | 2014-02-11 | Johnson & Johnson Vision Care | Contact lens with light blocking ring |
TW201410265A (en) * | 2012-07-31 | 2014-03-16 | Johnson & Johnson Vision Care | Lens incorporating myopia control optics and muscarinic agents |
CN102439512B (en) * | 2009-03-25 | 2014-12-10 | 高效光学技术有限公司 | Photochromic ophthalmic systems that selectively filter specific blue light wavelengths |
TWI500992B (en) * | 2012-05-11 | 2015-09-21 | Benq Materials Corp | Method for forming contact lenses and contact lenses therefrom |
-
2016
- 2016-09-30 TW TW110130739A patent/TWI854148B/en active
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1213773C (en) * | 2000-12-07 | 2005-08-10 | 庄臣及庄臣视力保护公司 | Contact lens packaging solutions |
TWI322285B (en) * | 2004-08-19 | 2010-03-21 | Johnson & Johnson Vision Care | Tinted contact lenses with combined limbal ring and iris patterns |
TWI426318B (en) * | 2006-06-29 | 2014-02-11 | Johnson & Johnson Vision Care | Contact lens with light blocking ring |
CN102439512B (en) * | 2009-03-25 | 2014-12-10 | 高效光学技术有限公司 | Photochromic ophthalmic systems that selectively filter specific blue light wavelengths |
TWI500992B (en) * | 2012-05-11 | 2015-09-21 | Benq Materials Corp | Method for forming contact lenses and contact lenses therefrom |
TW201410265A (en) * | 2012-07-31 | 2014-03-16 | Johnson & Johnson Vision Care | Lens incorporating myopia control optics and muscarinic agents |
Also Published As
Publication number | Publication date |
---|---|
TW202144867A (en) | 2021-12-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TWI641892B (en) | Contact lens and contact lens product | |
CN105445959B (en) | Free form lens design and method for preventing and/or slowing myopia progression | |
AU2015218500B2 (en) | Mask lens design and method for preventing and/or slowing myopia progression | |
TWI587035B (en) | Asymmetric lens design and method for preventing and/or slowing myopia progression | |
TWI665489B (en) | Pupil size-independent lens design for preventing and/or slowing myopia progression | |
CN107219640B (en) | Multifocal lens design and method for preventing and/or slowing myopia progression | |
TWI665490B (en) | High plus treatment zone lens design for preventing and/or slowing myopia progression | |
CN108205208A (en) | Height plus center treatment region lens design and the method for preventing and/or slowing down myopia progression | |
TWI696862B (en) | Contact lens and contact lens product | |
TW201533498A (en) | Contact lenses with improved oxygen transmission | |
CN101559009B (en) | Corneal contact lens with iris | |
TWI854148B (en) | Contact lens and contact lens product | |
TWI740504B (en) | Contact lens and contact lens product | |
EP2913703A1 (en) | Contact lenses with apparent motion and other optical effects | |
US20240402519A1 (en) | Contact lenses combining chromaticity and defocus for myopia control | |
CN220289980U (en) | Pupil-shading contact lens | |
TWI749646B (en) | Contact lens and product thereof |